Back to Trial

Oracle Runs

Oracle findings and outcome history for Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) (NCT05996835).

Runs
5
Findings
5
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial status Active Not Recruiting, estimated primary completion Feb 2026. No public readout of results found across web searches. Sources describe ongoing study without efficacy data or interpretation.

Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
ClinicalTrialsclinicaltrials.gov
NCT05996835 Phase 2b CLEAR-AKI Trial Record
Trial active not recruiting; purpose to evaluate safety/efficacy of TIN816 doses in SA-AKI. No results posted.
Web Searchasn-online.org
ASN Kidney Week Abstract on TIN816 Phase 2b
Phase 2b trial aims to characterize dose-response and evaluate safety/efficacy of TIN816 in SA-AKI patients.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public efficacy readout or topline results available for NCT05996835 Phase 2b CLEAR-AKI trial. Primary completion estimated 2026; current sources cover only protocol, PK/safety from prior Phase 2a, or preclinical data. No statements frame this specific trial as positive or negative.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
Web Searchclinicaltrials.gov
NCT05996835 | Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
Active, not recruiting. Estimated primary completion Feb 2026. No results posted.
Web Searchacademic.oup.comJan 1, 2025, 12:00 AM
#1152 Pharmacokinetics, pharmacodynamics and safety of TIN816 in patients with sepsis-associated acute kidney injury: Results From a Randomized Phase 2a Study
Reports PK/PD/safety from Phase 2a (not this Phase 2b trial). References ongoing Phase 2b but provides no efficacy data for NCT05996835.
Web Searchdelta.larvol.com
TIN816 / Novartis - LARVOL DELTA
Lists trial as ongoing Phase 2b. Notes only prior P2a PK/PD data; no CLEAR-AKI efficacy readout.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
ClinicalTrialsclinicaltrials.govMar 20, 2026, 12:00 AM
Study Details | NCT05996835 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-02-25; hasResults=false on the latest posted update.
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific Phase 2b efficacy readout was found. Current public trial records still describe CLEAR-AKI as ongoing/recruiting, with final analysis only after all participants complete Day 90. Without a public result framed as positive or negative for this exact trial, outcome cannot be classified.

Found Apr 3, 2026, 4:08 PMReviewed Apr 3, 2026, 4:47 PM
Sponsornovartis.comFeb 23, 2026, 12:00 AM
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) | Novartis
Novartis lists NCT05996835 as a Phase 2b CLEAR-AKI study, last updated Feb. 23, 2026; status shown as recruiting, completion May 19, 2026, and states final analysis will occur after all participants complete Day 90.
Web Searchfdaaa.trialstracker.net
NCT05996835: An ongoing trial by Novartis Pharmaceuticals
The public tracker labels NCT05996835 as an ongoing trial by Novartis, consistent with no completed public Phase 2b readout yet.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. As of Feb 23, 2026, Novartis still listed CLEAR-AKI as ongoing with planned interim/final analyses, and a trial database page shows 'No Results Posted.' Without a clear public interpretation for this exact Phase 2b trial, outcome cannot be classified positive or negative.

Found Apr 1, 2026, 7:14 PMReviewed Apr 1, 2026, 7:16 PM
Sponsornovartis.comFeb 23, 2026, 12:00 AM
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) | Novartis
Novartis trial page updated Feb 23, 2026 describes CLEAR-AKI as an ongoing Phase 2b study and says interim and final analyses are planned; it does not provide outcome data or a positive/negative readout.
Web Searchcdek.pharmacy.purdue.edu
Trial | NCT05996835 | Clinical Drug Experience Knowledgebase
The NCT05996835 trial page lists status as recruiting and, under 'Study Results,' states: 'No Results Posted.'
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.